


Amendments to the Claims



The listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

Claim 1 (original): A pharmaceutical composition for parenteral administration comprising a somatostatin analogue comprising the amino acid sequence of formula I




wherein X_1 is a radical of formula (a) or (b)



wherein R_1 is optionally substituted phenyl,

R_2 is $-\text{Z}_1-\text{CH}_2-\text{R}_1$, $-\text{CH}_2-\text{CO}-\text{O}-\text{CH}_2-\text{R}_1$,




wherein Z_1 is O or S, and

X_2 is an α -amino acid having an aromatic residue on the C_α side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys⁹ of the native somatostatin-14

in free form, salt form, or protected form and tartaric acid.

Claim 2 (original): A composition according to claim 1 wherein the somatostatin analogue is a compound of formula II



wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and

wherein R is $\text{NR}_1\text{R}_2\text{-C}_{2-6}\text{alkylene}$ or guanidine- $\text{C}_{2-6}\text{alkylene}$, and each of R_1 and R_2 independently is H or $\text{C}_{1-4}\text{alkyl}$,

in free form, salt form or protected form.

Claim 3 (previously presented): A composition according to claim 1 wherein the compound of the somatostatin analogue is in aspartate di-salt form.

Claim 4 (previously presented): A composition according to claim 1 wherein the composition is adjusted to a pH of about 4 to about 4.5.

Claim 5 (original): A composition for parenteral administration buffered at a pH of about 4 to about 4.5 and comprising as active ingredient cyclo[4-(NH₂-C₂H₄-NH-CO-O-)Pro]-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.


Claim 6 (original): A composition according to claim 5 wherein the composition is buffered by an acetate/acetic acid, lactate/ lactic acid, or Glycin / HCl buffer.

Claim 7 (currently amended): Use of a pharmaceutical composition according to claim 1 for the preparation of a medicament for ~~acromegaly or cancer~~ Cushing's Disease.

Claim 8 (original): Use according to claim 6 for the preparation of a medicament for Cushing's Disease.

Claim 9: Cancel

Claim 10 (original): A compound of formula III



wherein R is NR₁R₂-C₂₋₆alkylene or guanidine-C₂₋₆alkylene, and each of R₁ and R₂ independently is H or C₁₋₄alkyl,

in free form, in salt form or complex form, or in protected form, e.g. cyclo[{4-(NH₂-C₂H₄-NH-CO-O-)Pro}-DPhg-DTrp-Lys-Tyr(4-Bzl)-Phe].

11. (new) A pharmaceutical composition according to Claim 1 wherein the somatostatin analogue is cyclo[{4-(NH₂-C₂H₄-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

12. (new) A pharmaceutical composition according to claim 3 wherein the compound of the somatostatin analogue is cyclo[{4-(NH₂-C₂H₄-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

13. (new) A method of treating Cushing's Disease comprising administering a pharmaceutical compositions according to Claim 11.

14. (new) A method of treating Cushing's Disease comprising administering a pharmaceutical compositions according to Claim 12.